Targeting Fatty Acid Metabolism with Carotuximab to Restore Androgen Receptor Inhibitor Sensitivity in Prostate Cancer
5:40 pm - Thursday 18th March 2027
- Showing how carotuximab, a CD105-neutralizing antibody, blocks fatty acid oxidation in castration-resistant prostate cancer cells, increases oxidative stress and reshapes chromatin to restore sensitivity to androgen receptor signaling inhibitors
- Using epigenetic sequencing of circulating tumor DNA from pre- and post-treatment patient samples, supported by CT imaging, to reveal shared downregulation of androgen response, fatty acid oxidation and oxidative phosphorylation pathways across responders
- Highlighting how the kinetics of epigenetic remodeling, with an acute, extensive phase in poor responders versus stable, evenly distributed changes in strong responders, may distinguish treatment response
